Vyant Bio, Inc.VYNT

NASDAQHealthcareBiotechnology

A clinical-stage biotechnology company focused on developing therapies for rare and orphan diseases, particularly those affecting the central nervous system. Its lead programs target Rett syndrome and other neurodevelopmental disorders, with a pipeline that has attracted investor attention due to potential regulatory milestones. The company has faced financial challenges, including a reverse stock split to maintain listing compliance.

Congressional Interest in Vyant Bio, Inc. (VYNT)

1 member of Congress has disclosed 3 trades in Vyant Bio, Inc. (VYNT), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.